However, there is growing recognition that AD therapy needs to also address tau related pathology and recent reports have shown that active and passive immunotherapeutic approaches can successfully reduce tau aggregates and improve cognition in mouse models of AD [10,46]. Here, MAPT is linked to Alzheimer disease.